To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epilepsy, Partial Brain Diseases Central Nervous System Diseases Epilepsies, Partial Epilepsy Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pfizer Investigational Site, Bonn, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must have met the inclusion criteria for preceding double-blind study.
Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Pregnant or considering becoming pregnant.
Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Treatment and study plan

Pregabalin

Drug

Primary outcomes

Safety

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.

Important dates

Study start: 1997
Study completion: 2005
First posted: Sep 1, 2005
Registry last updated: Jan 1, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed